scholarly journals Data on the effect of maternal separation coupled with social isolation in a forced swim test and gene expression of glial fibrillary acid protein in the prefrontal cortex of rats

Data in Brief ◽  
2018 ◽  
Vol 18 ◽  
pp. 496-500 ◽  
Author(s):  
Yosuke Yamawaki ◽  
Misako Nishida ◽  
Kana Harada ◽  
Hiroyuki Akagi
2021 ◽  
pp. 1-7
Author(s):  
Dylan J. Terstege ◽  
Debra S. MacDonald ◽  
R. Andrew Tasker

Abstract Objective: Ginsenosides, biologically active components of the root of Panax ginseng, have been reported to have therapeutic benefits in a number of disease states including psychiatric conditions such as major depressive disorder. Our objective was to determine if a standardised commercial ginseng extract, G115®, could reduce the signs of behavioural despair commonly observed in animal models of depression either alone or in combination with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Methods: Male Sprague-Dawley (SD) rats (N = 51) were divided into four groups: vehicle control, G115® ginseng root extract, fluoxetine and fluoxetine plus G115®. Rats were trained to voluntarily consume treatments twice daily for 14 days and were then tested in an open field (OF), elevated plus maze (EPM) and forced swim test (FST). Post-mortem hippocampal and prefrontal cortex tissue was analysed for expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) by western blot. Results: One-way Analysis of Variance revealed no significant group differences in the OF or plus-maze performance on any variable examined. In the FST, fluoxetine significantly reduced immobility time and increased latency to immobility. The effects of fluoxetine were further significantly potentiated by co-administration of G115®. Post-mortem tissue analysis revealed significant group differences in BDNF expression in the left hippocampus and left prefrontal cortex without any accompanying changes in TrkB expression. Conclusions: We conclude that oral G115® significantly potentiates the antidepressant-like effect of fluoxetine in the FST in the absence of potentially confounding effects on locomotion and anxiety.


2015 ◽  
Vol 112 (19) ◽  
pp. 6188-6193 ◽  
Author(s):  
Jason M. Dwyer ◽  
Jaime G. Maldonado-Avilés ◽  
Ashley E. Lepack ◽  
Ralph J. DiLeone ◽  
Ronald S. Duman

Current treatments for major depressive disorder (MDD) have a time lag and are ineffective for a large number of patients. Development of novel pharmacological therapies requires a comprehensive understanding of the molecular events that contribute to MDD pathophysiology. Recent evidence points toward aberrant activity of synaptic proteins as a critical contributing factor. In the present studies, we used viral-mediated gene transfer to target a key mediator of activity-dependent synaptic protein synthesis downstream of mechanistic target of rapamycin complex 1 (mTORC1) known as p70 S6 kinase 1 (S6K1). Targeted delivery of two mutants of S6K1, constitutively active or dominant-negative, to the medial prefrontal cortex (mPFC) of rats allowed control of the mTORC1/S6K1 translational pathway. Our results demonstrate that increased expression of S6K1 in the mPFC produces antidepressant effects in the forced swim test without altering locomotor activity. Moreover, expression of active S6K1 in the mPFC blocked the anhedonia caused by chronic stress, resulting in a state of stress resilience. This antidepressant response was associated with increased neuronal complexity caused by enhanced S6K1 activity. Conversely, expression of dominant-negative S6K1 in the mPFC resulted in prodepressive behavior in the forced swim test and was sufficient to cause anhedonia in the absence of chronic stress exposure. Together, these data demonstrate a critical role for S6K1 activity in depressive behaviors, and suggest that pathways downstream of mTORC1 may underlie the pathophysiology and treatment of MDD.


2020 ◽  
Author(s):  
Jinqiang Zhang ◽  
Saini Yi ◽  
Yahui Li ◽  
Chenghong Xiao ◽  
Chan Liu ◽  
...  

AbstractAimIndoleamine 2, 3-dioxygenase (IDO) is responsible for the progression of the kynurenine pathway, which has been implicated in the pathophysiology of inflammation-induced depression. It has been reported that asperosaponin VI (ASA VI) could play a neuroprotective role through anti-inflammatory and antioxidant. In this study, we examined the antidepressant effect of ASA VI in LPS-treated mice and further explored its molecular mechanism by insight into the microglial kynurenine pathway.MethodsTo produce the model, lipopolysaccharide (LPS) (0.83 mg/kg) was administered intraperitoneally to mice. The mice received ASA VI (10 mg/kg, 20mg/kg, 40mg/kg and 80mg/kg, i.p.) thirty minutes prior to LPS injection. Depressive-like behaviors were evaluated based on the duration of immobility in the forced swim test. Microglial activation and inflammatory cytokines were detected by immunohistochemistry, real-time PCR and ELISA. The TLR4/NF-ĸB signaling pathway and the expression of IDO, GluA2, and CamKIIβ were measured by western blotting.ResultsASA VI demonstrated significant antidepressant activity in the presence of LPS on immobility and latency times in the forced swim test. The LPS-induced activation of microglia and inflammatory response were inhabited by ASA VI in a dose-dependent manner. TLR4/NF-κB signaling pathway also was suppressed by ASA VI in the hippocampus and prefrontal cortex of LPS-treated mice. Furthermore, ASA VI inhibited the increase in IDO protein expression and normalized the aberrant glutamate transmission in the hippocampus and prefrontal cortex as a result of LPS administration.ConclusionOur results propose a promising antidepressant effect for ASA VI possibly through the downregulation of IDO expression and normalization of the aberrant glutamate transmission. This remedying effect of ASA VI could be attributed to suppress microglia-mediated neuroinflammatory response via inhibiting the TLR4/NF-κB signaling pathway.


2021 ◽  
pp. 01-09
Author(s):  
Mehnaz Gitay ◽  
Kausar Saboohi ◽  
Bushra Chaudhary ◽  
Samina Bano

Since the discovery that antidepressants work in part by potentiating the actions of 5-HT within the serotonergic system the effects these drugs elicit on the serotonin transporter (SERT) protein have been an area of active research. The aim of the present study is to understand the mechanism of action of tianeptine and sertraline in relation to its effects on the expression of SERT gene and SERT protein in the brain stem of stressed rats. Albino Wistar rats were divided into two groups (n=12) i.e. saline and drug. Each group was further divided into two equal groups, stressed (Forced Swim Test-FST) and unstressed. Tianeptine and sertraline were administered to rats orally for 4 weeks prior to subjecting them to forced swim test and decapitation. Tianeptine increased the expression of SERT gene though the protein is reduced in the brain stem in stress. On the contrary sertraline decreased the expression of SERT gene but increased the protein in the brain stem. The increase in swimming time in FST by both the drugs indicates stress alleviating effects. It can be concluded that Tianeptine prevents stress induced changes through its effect on the serotonergic system, including SERT mRNA and protein. Sertraline complies to the reuptake inhibition property by reducing SERT gene expression. Results are discussed specifically, how changes in SERT expression following chronic antidepressant treatment may contribute to the therapeutic benefits of antidepressants. Keywords: Antidepressants; Serotonin transporters; Stress; Serotonergic system; SERT gene expression


Author(s):  
Roni Yankelevitch-Yahav ◽  
Motty Franko ◽  
Avrham Huly ◽  
Ravid Doron

2021 ◽  
Vol 165 ◽  
pp. 56-57
Author(s):  
Shota Naoe ◽  
Takahiro Kataoka ◽  
Hina Shuto ◽  
Junki Yano ◽  
Tetsuya Nakada ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document